Obeikan Glass Co

Obeikan Glass Co

9531.SR
Obeikan Glass CoSA flagSaudi Exchange
24.99
SAR
+0.52
- -
799.14MMarket Cap
Obeikan Glass Co
9531.SR
(Saudi Exchange)

Recent

price

24.99

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
2024
TTM
FRC
14.48
15.69
12.31
10.22
10.47
Revenue per Share
5.43
5.55
2.11
0.04
-0.09
Basic EPS, GAAP
4.92
3.29
3.6
-0.87
0.02
Free Cash Flow per Basic Share
0.75
1.5
- -
2
- -
Dividend per Share
12.01
15.57
17.46
15.5
17.49
Book Value per Share
13.06
16.75
19.61
17.41
17.94
Tangible Book Value per Share
32
32
32
32
32
Basic Weighted Avg Shares
463
502
394
327
334
Sales/Revenue/Turnover
39.89
38.53
19.81
9.97
8.71
Operating Margin (%)
37
39
40
40
43
Depreciation Expense
174
178
68
1
-3
Net Income, GAAP
3.33
3.64
8.68
448.13
31.29
Effective Tax Rate (%)
37.49
35.38
17.17
0.4
-0.87
Profit Margin (%)
143
184
264
162
177
Working Capital
136
22
31
24
24
LT Debt
418
536
628
557
573
Total Equity
- -
29.22
11.05
-17.34
- -
Return on Invested Capital (%)
- -
30.33
12.43
-1.35
7.59
Return on Capital (%)
- -
40.24
12.8
0.25
-0.54
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
59
49
82
LT Borrowings
3
3
3
LT Finance Leases
22
22
21
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
32
32
32
Market Capitalization
1,536
1,299
1,188

Working Capital

FRC

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
259
248
303
Cash, Cash Equivalents & STI
34
25
54
Accounts Receivable, Net
116
138
152
Inventories
51
35
45
Total Current Liabilities
97
85
125
Payables & Accruals
- -
- -
- -
ST Debt
59
49
82
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-11.21%
Free Cash Flow
- -
- -
-124.16%
Net Income, GAAP
- -
- -
-98.05%
Sales/Revenue/Turnover
- -
- -
-16.97%
Total Cash Common Dividend
- -
- -
33.33%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
113
103
94
84
394
2024
84
83
88
72
327
2025
85
89
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
0.93
0.76
0.55
- -
2.11
2024
0.33
0.39
0.32
- -
0.04
2025
0.19
0.4
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
2
- -
- -
- -
2
2025
- -
- -
- -
- -
- -
Business
Al Obeikan Glass Company Al Obeikan Glass Company (9531.SR) manufactures and sells float glass, laminated glass, and related products for architectural, automotive, and specialty applications; operates in wholesale and retail trade of glass panels and chemicals; and manages quarries and sand/gravel mining including crushers. The company produces clear float glass under the Nova Float brand in thicknesses from 3mm to 12mm with a capacity of 800 tons per day, alongside laminated safety glass under the Nova Lam brand that holds together when shattered via polyvinyl butyral interlayers. Its state-of-the-art facility, the largest of its kind in the Middle East, spans 378,400 square meters in Yanbu Industrial City on Saudi Arabia's Red Sea coast, supporting exports to over 30 countries across Africa, Asia, Europe, the Americas, and the Pacific. Incorporated in 2006 and headquartered in Riyadh, Saudi Arabia, with its main plant in Yanbu, Al Obeikan Glass Company (9531.SR) went public on the Tadawul in February 2022 and serves construction, automotive, and industrial markets primarily in Saudi Arabia and internationally. In recent developments, the company completed the full acquisition of Obeikan AGC Co. in 2025 for SAR 22.9 million, securing 100% ownership after previously holding 19%, following a sale and purchase agreement in August 2025 with partners including AGC France Holding, Obeikan Investment Group, and Saudi Advanced Industries Company Saudi Advanced Industries Company (2120.SR). It also launched commercial operations at a new aluminum casting plant in Madinah in 2025, a SAR 73 million joint venture with Al-Esra Aluminum Factory (60% owned by Al Obeikan Glass Company (9531.SR)) signed in August 2023, with trial runs starting December 2024 and financial impacts expected from Q4 2025 to enhance production capacity.